AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21591944
Drug: Selenium (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium (100 μg twice daily)
Trial: 21591944
Drug: Pentoxifylline (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (600 mg twice daily)
Trial: 19246990
Drug: HCV Core
RxNorm normalized name: HCV-086
DrugBank: HCV-086 (DB05884)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCV Core ISCOMATRIX vaccine (5, 20, or 50 microg HCV Core protein with 120 mug ISCOMATRIX adjuvant)
Trial: 7886411
Drug: Lignocaine 400
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine 400 mg (40 ml of a 1% solution) instilled for 1 hour in Group A patients (n = 9)
Trial: 29290184
Drug: Intense Pulse
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intense Pulse Light Therapy (IPL) and Triple Combination Cream (TCC)
Trial: 29290184
Drug: Intense Pulse
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intense Pulse Light Therapy (IPL)
Trial: 18235121
Drug: Imatinib 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib 600 mg/d
Trial: 16284710
Drug: Microtip and
RxNorm normalized name: Babesia microti preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microtip and water pressure transducer combination
Trial: 11306153
Drug: Four-drug combination
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-drug combination with protease inhibitor (PI) and non-nucleoside reverse transcriptase inhibitor (NNRTI) plus nucleoside analogue (NRTI) drugs
Trial: 11306153
Drug: Three-drug combinations
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-drug combinations (PI followed by NNRTI or NNRTI followed by PI)
Trial: 9736326
Drug: Bromocriptine (BRC)
DrugBank: Bromocriptine (DB01200)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bromocriptine (BRC) 2.5 mg daily
Trial: 2741861
Drug: Furosemide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (1 mg/kg IV every 24 hours)
Trial: 2741861
Drug: Ethacrynic acid
RxNorm normalized name: Ethacrynic Acid
DrugBank: Etacrynic acid (DB00903)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethacrynic acid (1 mg/kg IV every 24 hours)
Trial: 2741861
Drug: Furosemide and
RxNorm normalized name: furosemide and potassium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide and ethacrynic acid (alternating doses)
Trial: 22008766
Drug: No isoniazid
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No isoniazid preventive therapy (non-completers)
Trial: 30795794
Drug: Alpha power-maximisation
RxNorm normalized name: One-Alpha
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha power-maximisation anaesthesia titration strategy during maintenance phase of anaesthesia
Trial: 30795794
Drug: Early cessation
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early cessation of volatile anaesthesia and emergence from an intravenous infusion of propofol during emergence phase of anaesthesia
Trial: 29429537
Drug: Beverage containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beverage containing 20 g of soluble fiber dextrin (SFD)
Trial: 29429537
Drug: Beverage containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beverage containing 0 g of soluble fiber dextrin (control)
Trial: 29429537
Drug: Beverage containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beverage containing 10 g of soluble fiber dextrin (SFD)
Trial: 24072776
Drug: MASS criteria
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MASS criteria evaluation after therapy
Trial: 24072776
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of baseline serum LDH levels and MASS criteria evaluation
Trial: 22855276
Drug: N(G)-nitro-l-arginine methyl
RxNorm normalized name: methyl L-arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N(G)-nitro-l-arginine methyl ester (l-NMMA)
Trial: 20199883
Drug: Circulating lipids
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Circulating lipids measurement, oral glucose tolerance test (OGTT), and hormonal screening including GH secretory capacity (GHRH/arginine test).
Trial: 20199883
Drug: Assessment of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assessment of visceral to subcutaneous abdominal fat ratio.
Trial: 20199883
Drug: Correlation analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation analysis of visceral abdominal fat fraction with subcutaneous fat, BMI, and peak GH-response.
Trial: 20199883
Drug: Sex-steroid replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sex-steroid replacement therapy.
Trial: 3291526
Drug: dDAVP treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dDAVP treatment
Trial: 11890429
Drug: Real acupuncture
RxNorm normalized name: REAL FOODS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real acupuncture treatment with needles
Trial: 8847017
Drug: Locoregional immunostimulation
RxNorm normalized name: IMMUNOSTIMULANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locoregional immunostimulation and locoregional chemotherapy (Proleukin and Imukin infusion for 10 days, followed by locoregional chemotherapy 15 days later)
Trial: 1904189
Drug: Invasive versus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invasive versus conservative treatment strategies
Trial: 1904189
Drug: Early versus
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early versus delayed beta-blocker therapy
Trial: 7264274
Drug: Oral diethylcarbamazine
RxNorm normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral diethylcarbamazine (DEC)
Trial: 28073858
Drug: Fractional-dose inactivated
RxNorm normalized name: Poliovirus, inactivated, fractional-dose (fIPV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional-dose inactivated poliovirus vaccine (fIPV) administered intradermally on days 0 and 28
Trial: 28073858
Drug: Full-dose inactivated
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose inactivated poliovirus vaccine (IPV) administered intramuscularly on days 0 and 28
Trial: 24975432
Drug: Oral morphine
RxNorm normalized name: morphine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral morphine as first-line treatment
Trial: 24975432
Drug: Oral oxycodone
RxNorm normalized name: oxycodone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oxycodone as first-line treatment
Trial: 24975432
Drug: Oral morphine
RxNorm normalized name: morphine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral morphine as second-line treatment after switching
Trial: 24975432
Drug: Oral oxycodone
RxNorm normalized name: oxycodone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oxycodone as second-line treatment after switching
Trial: 24975432
Drug: Adverse reactions
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adverse reactions to oral morphine
Trial: 24975432
Drug: Adverse reactions
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adverse reactions to oral oxycodone
Trial: 23171815
Drug: Exercise augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise augmentation with 16 kilocalories per kilogram of body weight per week (KKW) for 12 weeks
Trial: 23171815
Drug: Exercise augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise augmentation with 4 KKW for 12 weeks
Trial: 23171815
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitor (SSRI) augmentation
Trial: 19519257
Drug: Methylphenidate transdermal
RxNorm normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate transdermal system (MTS) applied to the hip area
Trial: 19519257
Drug: Methylphenidate transdermal
RxNorm normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate transdermal system (MTS) applied to the scapular area
Trial: 18269868
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine plus glimepiride 3 mg
Trial: 18269868
Drug: Premixed 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premixed 30 R insulin (70/30) twice‐daily plus glimepiride 3 mg
Trial: 15287454
Drug: Cerebral perfusion
RxNorm normalized name: Sus scrofa cerebral cortex preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebral perfusion pressure (CPP) targeted therapy
Trial: 9439559
Drug: Healthy-living advice
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy-living advice and sulfonylurea therapy
Trial: 31448832
Drug: 1.2% SMV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2% SMV gel and covering the defect with occlusive membrane (OM)
Trial: 31448832
Drug: 1.2% SMV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2% SMV gel and covering the defect with perforated barrier membranes (PBM)
Trial: 31448832
Drug: 24% EDTA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24% EDTA root surface etching, 1.2% SMV gel, and defect coverage with occlusive membrane (eOM)
Trial: 31448832
Drug: 24% EDTA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24% EDTA root surface etching, 1.2% SMV gel, and defect coverage with perforated barrier membranes (ePBM)
Trial: 25404537
Drug: 5-HT3 receptor
RxNorm normalized name: 5-HT3 receptor antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-HT3 receptor antagonist
Trial: 23422652
Drug: Daily G-CSF
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily G-CSF administration
Trial: 23422652
Drug: Every other
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every other day G-CSF administration
Trial: 17029276
Drug: Low-dose interferon-alpha-2b
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-dose interferon-alpha-2b (IFN1) at a dose of 0.5 million units (MU) given subcutaneously twice daily
Trial: 17029276
Drug: Intermediate-dose interferon-alpha-2b
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermediate-dose interferon-alpha-2b (IFN5) at a dose of 5 MU given subcutaneously daily
Trial: 14990561
Drug: High-dose phase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose phase (HP) after 4 months of OC use at 45% Vo(2 peak)
Trial: 14990561
Drug: High-dose phase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose phase (HP) after 4 months of OC use at 65% Vo(2 peak)
Trial: 8504632
Drug: L-Dihydroxyphenylalanine infusion
RxNorm normalized name: L-3,4-dihydroxyphenylalanine
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: L-Dihydroxyphenylalanine infusion (0.33 micrograms min‐1 kg‐1)
Trial: 3308617
Drug: Vidarabine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vidarabine (15 mg/kg/day for 7 days then 7.5 mg/kg/day for 14 days)
Trial: 28424081
Drug: Increased vegetable
RxNorm normalized name: Hydrogenated Vegetable Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased vegetable portion sizes (150 g instead of 75 g) and decreased meat portion sizes (average reduction of 12.5%) during the intervention period.
Trial: 29895556
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine 100 units/mL (Gla‐100)
Trial: 22938664
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine and regular insulin injection (experiment group)
Trial: 22938664
Drug: Subcutaneous regular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous regular insulin injection (control group)
Trial: 19283567
Drug: Pharmacologic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacologic treatment (psychoactive medication)
Trial: 19283567
Drug: Non-pharmacologic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-pharmacologic treatment approaches
Trial: 17602983
Drug: Beta-blocker therapy
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker therapy (general)
Trial: 7846537
Drug: Doxorubicin (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (45 mg/m2)
Trial: 7846537
Drug: Epirubicin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin (60 mg/m2)
Trial: 7846537
Drug: Epirubicin (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin (90 mg/m2)
Trial: 2695500
Drug: 3 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 Gy daily on 20 consecutive days (total dose 60 Gy, TDF factor 123)
Trial: 2695500
Drug: 4 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 Gy 3 times per week until 12 irradiations (total dose 48 Gy, TDF factor 103)
Trial: 28727591
Drug: EMLA (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMLA (daily use for 4 weeks as a primary dressing)
Trial: 11778111
Drug: Ropivacaine 0.5%
RxNorm normalized name: ROPivacaine 0.5% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.5% combined with sufentanil 30 mcg (group S)
Trial: 11778111
Drug: Ropivacaine 0.5%
RxNorm normalized name: ROPivacaine 0.5% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.5% combined with morphine 2 mg (group M)
Trial: 11778111
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2% plus sufentanil 0.5 mcg/ml (group S)
Trial: 11778111
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2% plus morphine 0.02 mg/ml (group M)
Trial: 9596230
Drug: Frequent aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Frequent aspirin use
Trial: 9596230
Drug: Infrequent aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infrequent aspirin use
Trial: 9596230
Drug: Aspirin use
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin use (frequent and infrequent)
Trial: 2576364
Drug: Picumast dihydrochloride
RxNorm normalized name: Levocetirizine Dihydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Picumast dihydrochloride (2 mg o.d.)
Trial: 1278006
Drug: Forced water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forced water diuresis (oral or parenteral fluid)
Trial: 1278006
Drug: Furosemide in
RxNorm normalized name: furosemide Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide in high dosage
Trial: 23597577
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg daily for 7 days prior to PCI
Trial: 22090167
Drug: Colchicine 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 1.0 mg twice daily starting on postoperative day 3 followed by a maintenance dose of 0.5 mg twice daily for 1 month (doses halved for patients <70 kg or intolerant)
Trial: 9935260
Drug: Trovafloxacin (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trovafloxacin (intravenous alatrofloxacin followed by oral trovafloxacin for a maximum of 14 days)
Trial: 9935260
Drug: Cefoxitin followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin followed by amoxicillin/clavulanic acid (control group)
Trial: 15374296
Drug: CDP-choline 1000
RxNorm normalized name: CDP-choline
DrugBank: Citicoline (DB12153)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDP-choline 1000 mg/day i.m.
Trial: 2907743
Drug: Metoprolol (low-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (low-dose beta-blockade starting with 6.25 mg twice daily, increasing to a maximum of 100 mg as tolerated)
Trial: 2907743
Drug: Placebo (relative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (relative placebo group receiving standard therapy including digitalis, diuretics, vasodilators, and anticoagulants as needed)
Trial: 26370724
Drug: 2 mL
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL of 2% lidocaine with epinephrine
Trial: 25160518
Drug: Once-daily tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily tacrolimus extended release (Tac-ER)
Trial: 25160518
Drug: Twice-daily tacrolimus
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily tacrolimus immediate release (Tac-IR)
Trial: 22268509
Drug: Single-plane treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-plane treatment with 4.0 MHz, 4.5-mm depth transducer
Trial: 22268509
Drug: Dual-plane treatment
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-plane treatment with 4.0 MHz, 4.5-mm depth followed by 7.0 MHz, 3.0-mm depth transducer
Trial: 22268509
Drug: Both single-plane
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both single-plane and dual-plane treatments
Trial: 19281927
Drug: rHDL (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHDL (80 mg/kg of apolipoprotein A-I)
Trial: 12237626
Drug: Fluoxetine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine with oral contraceptives
Trial: 12237626
Drug: Fluoxetine without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine without oral contraceptives
Trial: 9842788
Drug: Fluvoxamine (50-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (50-300 mg)
Trial: 7989026
Drug: HMO members
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HMO members receiving antipsychotic drugs or lithium
Trial: 30987658
Drug: Songling Xuemaikang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Songling Xuemaikang capsules (SXC)
Trial: 28834608
Drug: Factors associated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Factors associated with verification at 10 ng/ml
Trial: 26332857
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine (DEX) 0.5 μg·kg IV bolus
Trial: 23320520
Drug: AZD1386 (95
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1386 (95 mg single dose)
Trial: 15146408
Drug: COBRA therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COBRA therapy (including temporary high-dose prednisolone, temporary low-dose methotrexate, and sulfasalazine)
Trial: 11535840
Drug: 0.2 percent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 percent nitroglycerin ointment (n = 19)
Trial: 8294171
Drug: Nalbuphine 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine 0.3 mg.kg-1
Trial: 26709060
Drug: Ezetimibe and
RxNorm normalized name: Ezetimibe and Simvastatin Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe and low-dose simvastatin
Trial: 23597333
Drug: Expectancy group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expectancy group (placebo cream applied)
Trial: 23597333
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no placebo cream applied)
Trial: 16672069
Drug: PSQ-An Treatment
RxNorm normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PSQ-An Treatment burden subscale
Trial: 11008329
Drug: Fosinopril (5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril (5-20 mg/day)
Trial: 11008329
Drug: No ACE-inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No ACE-inhibitor therapy (Control group)
Trial: 9103725
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy (16 weekly sessions)
Trial: 9103725
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (6-12 weeks)
Trial: 8095251
Drug: Verapamil 240
RxNorm normalized name: verapamil 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 240 mg (once a day)
Trial: 8095251
Drug: Captopril 20
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril 20 mg (twice a day)